Sodium alginate and GelMA composite hydrogel 3D pancreatic duct stent and preparation method thereof
The pancreatic duct stent prepared by 3D printing technology of sodium alginate and GelMA composite hydrogel solves the problem of inflammatory response caused by non-degradable stents in the treatment of existing pancreatic duct stenosis, provides good biocompatibility and mechanical properties, and achieves The self-degradation and long-term stability of the stent improve the safety and efficacy of the treatment.
Patent Information
- Application Number
- CN202411011877.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-08
AI Technical Summary
In the existing endoscopic interventional treatment of pancreatic duct stenosis, plastic and metal stents are not degradable. Long-term placement will lead to inflammatory reactions and toxic side effects, limiting its application scope and efficacy.
The 3D pancreatic duct scaffold was prepared by bio3D printing technology using sodium alginate and GelMA composite hydrogel. It has good biocompatibility and mechanical properties, and can degrade itself in the body, avoiding the need for secondary surgery.
This composite hydrogel 3D pancreatic duct stent has good biocompatibility and mechanical properties, reduces adverse reactions, can degrade itself in the body, avoids inflammatory reactions and toxic side reactions, and provides long-term mechanical support and expansion effects. No secondary surgery is required.
Smart Images

Figure CN118903566A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomaterials, and in particular relates to a sodium alginate and GelMA composite hydrogel 3D pancreatic duct stent and a preparation method thereof. Background Art
[0002] Pancreatic duct stenosis is a common pathophysiological change caused by pancreatic diseases such as chronic or acute pancreatitis, trauma, surgical complications, pseudocysts, and malignant diseases around the pancreatic head and ampulla. It can lead to obstructed pancreatic juice outflow, high pressure and local ischemia in the pancreatic parenchyma, induce abdominal pain, and accelerate pancreatic endocrine and exocrine dysfunction. Dilation of the pancreatic duct and unobstructed drainage are the core of the treatment of pancreatic duct stenosis. With the continuous improvement of endoscopic retrograde pancreaticocholangiopancreatography (ERCP), endoscopic treatment has gradually become the first-line treatment for pancreatic duct stenosis, and pancreatic duct stent placement is a common method in endoscopic treatment.
[0003] At present, most pancreatic stents used in clinical practice are plastic stents and self-expanding metal stents. Plastic pancreatic duct stents alleviate pancreatic duct stenosis to a certain extent, but their disadvantages are that the diameter of the plastic pancreatic duct stent is small, and it cannot significantly expand the stenotic section of the pancreatic duct, and it cannot adapt to the physiological curvature of the pancreatic duct. The fit between the stent and the pancreatic duct is poor, and the plastic stent is prone to collapse, causing the duct to narrow again; the self-expanding metal stent has a larger diameter than the plastic stent and has a stronger supporting capacity, but its disadvantage is that the stent is easily displaced and needs to be removed by surgery for a second time, and according to clinical records, long-term presence in the body will produce certain systemic and local toxic and side effects. That is, in the existing endoscopic interventional treatment of pancreatic duct stenosis, plastic stents and metal stents are non-degradable, and need to be removed by surgery for a second time. Long-term placement will produce inflammatory reactions and toxic and side effects, which limits its scope of application and efficacy. Summary of the invention
[0004] In order to solve the problems in the existing endoscopic interventional treatment of pancreatic duct stenosis that plastic stents and metal stents are non-degradable, long-term placement will cause inflammatory reactions and toxic side effects, and their application in medical fields such as clinical disease treatment of pancreatic duct stenosis is limited, the present invention provides a sodium alginate and GelMA composite hydrogel 3D pancreatic duct stent and a preparation method thereof.
[0005] The technical solution adopted by the present invention is: a method for preparing a sodium alginate and GelMA composite hydrogel 3D pancreatic duct scaffold, sodium alginate SA, methacrylated gelatin GelMA and a photoinitiator are mixed to form biological ink, and a 3D pancreatic duct scaffold is prepared by biological 3D printing technology.
[0006] Preferably, the specific preparation method is as follows:
[0007] Step 1: Add SA to the GelMA hydrogel prepolymer solution, then add PBS buffer and photoinitiator to obtain the GelMA / SA composite hydrogel prepolymer solution;
[0008] Step 2: Design the shape of the pancreatic duct stent, use a sterile biological 3D printer, and use the GelMA / SA composite hydrogel prepolymer as the 3D printing biological ink to print the pancreatic duct stent. The outlet is collected with CaCl2 solution and cured by ultraviolet light to obtain a 3D pancreatic duct stent.
[0009] Preferably, the SA mass concentration is 1%-4% (w / v).
[0010] Preferably, the mass concentration of GelMA is 7.5%-10% (w / v).
[0011] Preferably, the photoinitiator is Irgacure 2959, and the added amount is 0.75%-1% (w / v).
[0012] Preferably, the pancreatic duct is designed to have a length of 3-8 cm and an inner diameter of 2-4 mm.
[0013] Preferably, adding drugs to the GelMA / SA composite hydrogel prepolymer solution can form a drug-loaded 3D pancreatic duct scaffold.
[0014] A 3D pancreatic duct scaffold is prepared by a method for preparing a sodium alginate and GelMA composite hydrogel 3D pancreatic duct scaffold.
[0015] The advantages and positive effects of the present invention are: the 3D pancreatic duct scaffold prepared by using GelMA and SA that conforms to the formation of hydrogel has better biocompatibility, can stimulate the local mucosa by scissors, thereby avoiding local tissue granulation hyperplasia leading to obstruction of the scaffold and reducing the occurrence of adverse reactions; the composite hydrogel 3D pancreatic duct scaffold has a dense structure and good mechanical properties. It is not easy to fall off or shift after implantation in the body and has good mechanical support properties; in addition, the composite hydrogel 3D pancreatic duct scaffold has better degradability and can degrade by itself 3-6 months after implantation in the human body, without the need for secondary surgery to remove it. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 Cytotoxicity of sodium alginate and GelMA composite hydrogel 3D pancreatic duct scaffold;
[0017] Figure 2 Degradability of sodium alginate and GelMA composite hydrogel 3D pancreatic duct scaffold;
[0018] Figure 3 Mechanical properties of sodium alginate and GelMA composite hydrogel 3D pancreatic duct scaffold. DETAILED DESCRIPTION
[0019] The embodiments of the present invention are described below with reference to the accompanying drawings.
[0020] The present invention relates to a sodium alginate and GelMA composite hydrogel 3D pancreatic duct stent and a preparation method thereof. Sodium alginate SA, methacrylated gelatin GelMA and a photoinitiator are mixed to form biological ink, and a 3D pancreatic duct stent is prepared by biological 3D printing technology. The prepared composite hydrogel 3D pancreatic duct stent replaces plastic materials and metal materials, has better biocompatibility with tissue mucosa in the body, and reduces the occurrence of adverse reactions; the 3D pancreatic duct stent also has better strength and is degradable, and does not require secondary surgery when used, and can be directly degraded.
[0021] The specific preparation method of sodium alginate and GelMA composite hydrogel 3D pancreatic duct scaffold is as follows:
[0022] Step 1: Add SA to the GelMA hydrogel prepolymer solution, then add PBS buffer, and add a photoinitiator to obtain a GelMA / SA composite hydrogel prepolymer solution; wherein the SA mass concentration is 1%-4% (w / v), specifically 1% (w / v), 2% (w / v) or 4% (w / v); the GelMA mass concentration is 7.5%-10% (w / v), specifically 7.5% (w / v), 10% (w / v); the photoinitiator is Irgacure2959, and the addition amount is 0.75%-1% (w / v);
[0023] Step 2: Design the shape of the pancreatic duct stent with a length of 3-8 cm and an inner diameter of 2-4 mm. Use a sterile biological 3D printer to print the pancreatic duct stent using GelMA / SA composite hydrogel prepolymer as the 3D printing biological ink. Collect the CaCl2 solution at the outlet and cure it with UV light to obtain a 3D pancreatic duct stent.
[0024] The prepared 3D pancreatic duct stent can be directly used for surgical implantation. Using polymer biomaterials such as GelMA and SA instead of plastic and metal materials: it has better biocompatibility with the tissue mucosa in the body, reduces stimulation to the local mucosa, thereby avoiding local tissue granulation hyperplasia leading to stent obstruction and reducing adverse reactions; it can degrade on its own 3-6 months after implantation in the human body, without the need for secondary surgery to remove it; it has a dense structure and good mechanical properties, and is not easy to fall off or shift after implantation in the body. It has good mechanical support properties for pancreatic duct stenosis caused by chronic pancreatitis, and can maintain expansion and drainage of the stenotic area for a long time. The degradable pancreatic duct stent can be implanted into the patient's body using endoscopic interventional surgery, which causes less pain and faster recovery.
[0025] In certain embodiments of the present invention, drugs can also be added to the GelMA / SA composite hydrogel prepolymer to form a drug-loaded 3D pancreatic duct stent. The stent can also produce corresponding drug effects at the location where it is inserted into the pancreatic duct. The sodium alginate and GelMA composite hydrogel 3D pancreatic duct stent is prepared using 3D printing technology. After systematically evaluating the patient's condition, pancreatic duct stents of different specifications and different degradation times can be customized according to the patient's condition, making the manufacture of personalized medical equipment possible, and pancreatic duct stenosis can also be managed more effectively.
[0026] The scheme of the present invention is described below in conjunction with the accompanying drawings, wherein the experimental methods without specific operating steps are all carried out in accordance with the corresponding product instructions, and the instruments, reagents, and consumables used in the examples can all be purchased from commercial companies unless otherwise specified.
[0027] Example 1: Preparation of sodium alginate and GelMA composite hydrogel
[0028] 10 g of gelatin was mixed with 100 mL of PBS, and 8 ml of methacrylic anhydride (MA) was added after the mixture was completely dissolved; 100 ml of PBS was added to the mixture of Gelatin and MA to obtain a GelMA hydrogel prepolymer solution.
[0029] SA particles were dissolved in GelMA hydrogel prepolymer solution, and the mixture was dissolved in PBS, and 1% (w / v) Irgacure 2959 photoinitiator was added to obtain GelMA / SA composite hydrogel prepolymer solution. SA particles and GelMA can be mixed according to different mass fractions, and GelMA / SA composite hydrogels with different contents can be prepared according to the data in Table 1.
[0030] Table 1 GelMA / SA composite hydrogel sample composition
[0031]
[0032] A pancreatic duct stent of appropriate size and shape was designed using CAD software, and a sterile biological 3D printer was used to print the pancreatic duct stent using the above 8 composite hydrogel prepolymer solutions as 3D printing biological inks. The solution was collected at the outlet and cured by ultraviolet light to obtain 8 different composite hydrogel degradable pancreatic duct stents.
[0033] The cytotoxicity of the eight prepared GelMA / SA composite hydrogels was tested. 3×10 3Individual pancreatic duct epithelial cells were cultured for 24 hours; the cell culture medium was replaced with freeze-dried GelMA / SA composite hydrogel extract and cultured for 1, 3, and 5 days respectively; CCK-8 reagent was added and incubated in a constant temperature incubator at 37°C for 2 hours, and the absorbance value was measured with an enzyme marker at a wavelength of 450nm. Figure 1 As shown. According to GB / T 16886.5-2017 / ISO 10993-5:2009, the cell survival rate is <70% of the blank group, indicating that the material has potential cytotoxicity. The cytotoxicity of each group of materials is greater than 80%, indicating that the material has low cytotoxicity and good biocompatibility, especially the 1#-7# composite hydrogel has excellent biosafety.
[0034] The degradation of the eight prepared hydrogels was then tested. The freeze-dried GelMA / SA composite hydrogels were weighed and immersed in simulated pancreatic juice at 37°C, and the solution was changed weekly. After 1, 3, 5, 7, 14, and 21 days of degradation, the hydrogels were freeze-dried and weighed, and the degradation rates were calculated. The results are shown in Figure 2. Figure 2 Among them, 1# hydrogel and 5# hydrogel both degrade rapidly and are overlapped in the figure; 2#, 3#, 4#, 7#, and 8# composite hydrogels degrade more slowly and are more suitable for preparing pancreatic duct stents.
[0035] The mechanical properties of the eight prepared hydrogels were tested. The freeze-dried GelMA / SA composite hydrogel samples were placed in PBS at 4°C for 24 hours to achieve equilibrium swelling. The samples were compressed at a speed of 1 mm / min using a biomechanical testing machine (QX-W100, China) to obtain the compressive strength of the samples. Figure 3 As shown, 2# and 3# hydrogels have better mechanical properties.
[0036] Example 2: 3D printed biodegradable drug-loaded pancreatic duct stent
[0037] Mix 10g of gelatin with 100mL of PBS, add 8ml of methacrylic anhydride (MA) after it is completely dissolved; add 100ml of PBS and 1% (w / v) Irgacure2959 photoinitiator to the mixture of gelatin and MA to obtain GelMA hydrogel prepolymer solution. The GelMA hydrogel prepolymer solution can be stored by freeze-drying, and the GelMA polymer foam is obtained after dialysis, freezing, freeze-drying and other steps. After freeze-drying, it can be stored in a drying dish and directly dissolved with PBS when used.
[0038] The SA particles were dissolved in the GelMA hydrogel prepolymer solution, and then the two were dissolved in PBS, and 1% (w / v) Irgacure2959 photoinitiator was added to obtain the GelMA / SA composite hydrogel prepolymer solution. Among them, the concentrations of GelMA that can be added can be 1.5% (w / v), 5% (w / v), 7.5% (w / v), and 10% (w / v), and the concentrations of SA that can be added can be 2% (w / v) and 4% (w / v), respectively, and the specific concentrations can be selected according to the actual situation.
[0039] A certain dose of oxymatrine (OM) particles was dissolved in the GelMA / SA composite hydrogel prepolymer solution to obtain the OM@GelMA / SA composite hydrogel prepolymer solution.
[0040] The pancreatic duct stent designed by CAD software has a length of 3-8cm and a diameter of 2-4mm. The pancreatic duct stent is printed using a sterile biological 3D printer with OM@GelMA / SA composite hydrogel prepolymer as the 3D printing biological ink. The CaCl2 solution is collected at the outlet and cured by ultraviolet light to finally obtain the OM@GelMA / SA composite hydrogel degradable pancreatic duct stent.
[0041] The embodiments of the present invention are described in detail above, but the contents described are only preferred embodiments of the present invention and cannot be considered to limit the scope of implementation of the present invention. All equivalent changes and improvements made within the scope of the present invention should still fall within the scope of the patent coverage of the present invention.
Claims
1. A method for preparing a sodium alginate and GelMA composite hydrogel 3D pancreatic duct scaffold, characterized in that: Sodium alginate SA, methacrylated gelatin GelMA and photoinitiator were mixed to form bio-ink, and a 3D pancreatic duct scaffold was prepared by bio-3D printing technology.
2. The method for preparing the sodium alginate and GelMA composite hydrogel 3D pancreatic duct scaffold according to claim 1, characterized in that: The specific preparation method is as follows: Step 1: Add SA to the GelMA hydrogel prepolymer solution, then add PBS buffer and photoinitiator to obtain the GelMA / SA composite hydrogel prepolymer solution; Step 2: Design the shape of the pancreatic duct stent, use a sterile biological 3D printer, and use the GelMA / SA composite hydrogel prepolymer as the 3D printing biological ink to print the pancreatic duct stent. The outlet is collected with CaCl2 solution and cured by ultraviolet light to obtain a 3D pancreatic duct stent.
3. The method for preparing the sodium alginate and GelMA composite hydrogel 3D pancreatic duct scaffold according to claim 2, characterized in that: The SA mass concentration is 1%-4% (w / v).
4. The method for preparing the sodium alginate and GelMA composite hydrogel 3D pancreatic duct scaffold according to claim 2, characterized in that: The mass concentration of GelMA is 7.5%-10% (w / v).
5. The method for preparing the sodium alginate and GelMA composite hydrogel 3D pancreatic duct scaffold according to claim 2, characterized in that: The photoinitiator is Irgacure 2959, and the addition amount is 0.75%-1% (w / v).
6. The method for preparing the sodium alginate and GelMA composite hydrogel 3D pancreatic duct scaffold according to claim 2, characterized in that: The designed length of the pancreatic duct is 3-8 cm and the inner diameter is 2-4 mm.
7. The method for preparing the sodium alginate and GelMA composite hydrogel 3D pancreatic duct scaffold according to any one of claims 2 to 6, characterized in that: Adding drugs to the GelMA / SA composite hydrogel prepolymer solution can form a drug-loaded 3D pancreatic duct scaffold.
8. A 3D pancreatic duct stent, characterized in that: The 3D pancreatic duct scaffold is prepared by the method for preparing the sodium alginate and GelMA composite hydrogel 3D pancreatic duct scaffold described in any one of claims 1 to 7.
Citation Information
Cited By
Gelatin composite hydrogel ink for 3D coaxial printing as well as preparation method and application of gelatin composite hydrogel ink
CN119405905A
